Table 4.
Effect of SVPII on irradiated M-NFS-60 cell cycle progression (% of total cells)
| Group | G0-G1 | G2-M | S | Apoptosis |
|---|---|---|---|---|
| Control |
40.16 ± 3.40 |
6.69 ± 0.70 |
52.86 ± 4.83 |
0.01 ± 0.00 |
| Irradiated |
34.45 ± 1.75 |
31.71 ± 3.16 |
32.21 ± 2.65 |
15.81 ± 1.26 |
| IL-310 μg/L |
14.72 ± 0.91* |
65.38 ± 5.11* |
20.93 ± 2.76* |
31.95 ± 4.11* |
| SVPII 3 mg/L | 36.65 ± 2.07# | 46.27 ± 4.28*# | 16.92 ± 1.95*# | 21.09 ± 2.05*# |
Cells were unirradiated (Control), irradiated and then incubated for 48 h in media with 25% rhM-CSF (15.5 μg/L) for 48 h(Irradiated), or irradiated and then treated with 15.5 μg/L rhM-CSF + IL-3(IL-310 μg/L) or 15.5 μg/L rhM-CSF + SVPII(SVPII 3 mg/L). * P < 0.05 vs. irradiated group; #P < 0.05 vs. IL-310 μg/L group.